NAD+ and NMN are often presented as competing ways to support the same biological pathway, yet they are not interchangeable compounds. NAD+ is a fully formed coenzyme used directly in cellular metabolism, whereas NMN is a smaller precursor that the body can convert into NAD+ via its own biosynthetic pathways. This distinction becomes particularly important when comparing products. NMN is most commonly studied as an oral precursor, whereas direct NAD+ is available in forms such as intravenous infusions, injections, and oral or sublingual preparations.
The evidence base for these approaches also differs. Oral NMN has been evaluated in numerous controlled human trials and has been shown to increase NAD+-related biomarkers in the blood. Direct administration of NAD+, particularly via intravenous or injection routes, has significantly fewer controlled data on clinical outcomes regarding the frequently promoted anti-aging and general wellness applications. [2–5]
Therefore, a more useful question is not simply whether NAD+ or NMN is „better,” but what evidence exists for each route of administration, what was actually measured in humans, and to what extent these results correspond to the goal we are interested in.
NAD+ vs NMN?
NAD+ and NMN are different molecules connected within the same metabolic pathway.
NMN, or nicotinamide mononucleotide, is a precursor that can be converted into NAD+ by enzymes naturally present in the body. Products containing direct NAD+, on the other hand, attempt to deliver the ready-made NAD+ molecule. [1]
These roads are therefore fundamentally different.
In the case of NMN, the simplified process looks as follows:
NMN → NAD+
This transformation is catalyzed by enzymes called nicotinamide mononucleotide adenylyltransferases, or NMNAT. [1]
Direct NAD+ supplements theoretically bypass the precursor stage, as they provide preformed NAD+. However, the introduction of NAD+ into the bloodstream or the gastrointestinal tract does not automatically mean that we know how much intact NAD+ ultimately reaches various intracellular compartments.
Currently, most of the data from human studies pertain to precursors.
Randomized studies have shown that oral NMN can increase blood NAD+ levels. [2,4] By comparison, a 2026 systematic review of NAD+ interventions did not identify any eligible controlled clinical outcome studies of direct intravenous or intramuscular NAD+ administration for anti-aging or broadly defined wellness applications. [3]
This does not mean that the direct administration of NAD+ does not produce any biological effects.
Instead, it means that its widespread commercial use currently outpaces the strength of controlled human evidence regarding many of the benefits attributed to it.
How is NMN converted into NAD+ in the body?
NMN is very closely related to NAD+ in the body's biosynthetic pathways.
Once it enters the appropriate cellular pathways, NMN can be converted to NAD+ in reactions catalyzed by NMNAT enzymes. These enzymes add the remaining adenine-containing component needed to form NAD+. [1]
This short biochemical pathway is one of the reasons for the high level of interest in NMN as a precursor to NAD+.
Studies involving humans provide evidence that oral NMN may affect NAD+ metabolism.
In a randomized, multicenter, double-blind, placebo-controlled trial, 80 healthy middle-aged and older adults received 300, 600, or 900 mg of NMN daily for 60 days. Blood NAD+ levels increased in a dose-dependent manner in the groups receiving NMN. [2]
The researchers also noted improved results on the six-minute walk test in the groups receiving higher doses.
However, no significant improvement in insulin sensitivity was observed. [2]
This difference illustrates an important principle in NAD+ research: an increase in an NAD+-related biomarker does not automatically imply the occurrence of all subsequent physiological effects that might seem likely based on the biochemical mechanisms alone.
In a separate study involving healthy Japanese men, a single oral administration of NMN at doses up to 500 mg was evaluated. The researchers analyzed clinical parameters and nicotinamide metabolites and reported no significant safety issues during the study. [4]
Taken together, these studies suggest that oral NMN may be involved in NAD+ metabolism in humans.
However, they do not confirm that NMN is a treatment for aging or any specific disease.
Direct NAD+ vs. Precursor Supply: Advantages and Limitations
Direct NAD+ in an intravenous infusion, injection, or sublingual formulation
The rationale behind the direct administration of NAD+ seems simple: instead of supplying a precursor and relying on the body to complete the synthesis of NAD+, the fully formed molecule is administered.
Intravenous administration also bypasses the gastrointestinal tract.
This approach has become popular in wellness clinics and facilities offering infusion therapies, where NAD+ may be promoted in the context of energy, recovery, cognitive function, or anti-aging.
However, bypassing the gastrointestinal tract should not be equated with proven improved delivery of NAD+ to cells or with better clinical outcomes.
The evidence reviewed remains limited.
A 2026 systematic review found a significantly higher number of human interventional studies on oral NAD+ precursors than on direct intravenous or intramuscular NAD+ in anti-aging and wellness applications. No eligible controlled clinical outcome studies were identified regarding intravenous or intramuscular NAD+ in these applications. [3]
In another retrospective, real-world pilot study, intravenous NAD+ was compared with intravenous nicotinamide riboside, another NAD+ precursor. In this analysis, intravenous NAD+ was associated with a greater number of gastrointestinal and cardiovascular symptoms. [5]
Because this was a retrospective pilot study rather than a randomized controlled trial, it should not be considered definitive proof that intravenous NAD+ is less safe than strategies using precursors.
However, it shows why tolerance depending on the route of administration requires appropriate research, rather than assuming that direct administration is inherently better.
Oral NMN
NMN takes a different approach.
Instead of supplying ready-made NAD+, it supplies a naturally occurring intermediate compound that can enter the body's own NAD+ biosynthesis pathways.
Its main advantage, from an evidence-based perspective, is that oral NMN has been evaluated in randomized, placebo-controlled trials involving humans. These studies have shown an increase in NAD+-related biomarkers and, overall, good short-term tolerability. [2,4]
However, the evidence becomes less clear-cut when we move from NAD+ biomarkers to actual clinical outcomes.
An increase in NAD+ levels in the blood does not confirm improved cognitive function, a longer lifespan, increased energy, protection against disease, or the reversal of the aging process.
The evidence therefore supports a narrower conclusion: oral NMN can affect NAD+ metabolism in humans, while the broader clinical significance of this phenomenon is still being investigated.
Comparison of NAD+ and NMN: Absorption, Cost, and Form
| Feature | Direct NAD+ (IV/injection) | Direct NAD+ (sublingual/oral) | NMN (oral) |
|---|---|---|---|
| What does it deliver | Fully formed NAD+ | Fully formed NAD+ | NAD+ precursor |
| Basic trail | Direct administration of NAD+ | Direct administration of NAD+ | Conversion toward NAD+ by NMNAT |
| Method of administration | Intravenous infusion or injection | Sublingual or oral preparation | Capsule, tablet, or powder |
| Gastrointestinal tract | Bypassed when administered intravenously | It depends on the formulation | Oral absorption, followed by metabolism |
| Controlled human trials | Limited for anti-aging/wellness effects [3] | Limited | Many studies involving humans [2,4] |
| Evidence on NAD+ biomarkers | Less characterized in controlled outcome studies | Limited | An increase in blood NAD+ levels was demonstrated [2] |
| Tolerance data | Limited; retrospective data indicate route-dependent questions [5] | Inadequately characterized | Generally favorable in short-term human studies [2,4] |
| Typical availability | IV/wellness clinics and centers | Supplements market | Supplements market |
| Application complexity | Highest | Lower | Lower |
| Relative cost | Usually high due to the need for clinical administration | Variable | Usually more accessible |
Cost and availability can vary significantly depending on the country, formulation, supplier, and regulatory environment, and therefore should not be treated as fixed characteristics.
Most importantly, neither convenience nor price constitutes proof of biological efficacy.
Can NAD+ and NMN be used together?
Currently, there is not enough direct human research data to determine whether combining direct NAD+ administration with oral NMN provides additional benefits.
Both approaches ultimately affect the same NAD+ metabolic system.
NMN provides a precursor material that can be converted into NAD+, whereas direct administration of NAD+ provides the ready-made coenzyme.
It may therefore seem logical that their combination should produce a greater effect.
However, this has not been demonstrated.
Dedicated, controlled human studies would be needed to determine whether the combination of these interventions causes:
- greater availability of NAD+;
- no significant additional effect;
- altered metabolism;
- different responses in different tissues;
- additional adverse reactions;
- or clinically significant benefits outweighing each method used alone.
Without such data, defining NAD+ and NMN as a confirmed synergistic „stack” goes beyond the available evidence.
This is particularly important when direct NAD+ is administered intravenously or by injection, as these routes introduce additional administration and tolerance issues that do not occur in the same way with the oral precursor. [5]
What aligns better with a specific goal: energy, longevity, or focus?
The response requires, above all, the separation of confirmed biological effects from proposed health benefits.
NAD+ biomarker testing
If the question is specifically about which approach has stronger controlled human evidence for increasing NAD+-related biomarkers, oral precursors currently have a clearer evidence base.
Human studies show that oral NMN can increase blood NAD+ concentrations. [2,4]
A 2026 systematic review also showed that precursor interventions have a significantly greater number of controlled human trials than direct intravenous or intramuscular NAD+ used for anti-aging and wellness purposes. [3]
This does not mean that NMN provides better clinical outcomes.
It merely means that this specific biological effect has been better studied.
Energy and physical performance
NAD+ plays a central role in cellular energy metabolism, providing a strong mechanistic rationale for investigating interventions that increase its availability.
Improving NAD+ availability does not have to translate into a noticeable increase in energy or physical performance in humans.
Some studies on NMN have reported changes in physical performance outcomes, including the six-minute walk test. However, other metabolic markers did not consistently improve. [2]
Further research is needed before NAD+ or NMN can be considered proven interventions for increasing physical performance or helping to treat fatigue.
Longevity and aging
NAD+ biology is closely linked to aging research because NAD+ participates in mitochondrial metabolism, DNA repair, sirtuin activity, and other processes that change with age.
This provides a sound scientific basis for longevity research.
However, it does not imply a proven extension of human life.
Neither NMN nor direct NAD+ administration have been shown in robust controlled human studies to be methods that extend lifespan or reverse biological aging.
It is crucial to distinguish between an effect on the aging-related pathway and achieving a clinically significant anti-aging effect.
Cognitive functions
NAD+ metabolism is also studied in neuroscience because neurons have a high metabolic demand, and mitochondrial dysfunction occurs in many neurological diseases.
However, available evidence does not support either NMN or direct NAD+ as effective and proven methods for improving cognitive function.
Claims regarding memory, concentration, neuroprotection, or neurological diseases require data referring directly to these outcomes, rather than merely the fact that NAD+ participates in brain metabolism.
Direct intravenous or injectable NAD+
The idea that intravenous NAD+ should work better because it is delivered „directly” may seem intuitive, but it has not yet been adequately proven.
Intravenous administration bypasses gastrointestinal absorption.
This does not automatically mean better delivery of NAD+ to the interior of cells, greater tissue exposure, better clinical outcomes, or greater safety.
According to a 2026 systematic review, controlled clinical outcome data for intravenous or intramuscular NAD+ in anti-aging and wellness applications remained particularly limited. [3]
Therefore, the comparison most consistent with the evidence is not: „NAD+ works and NMN doesn't” or „NMN is better than NAD+”.
Currently, oral NMN has stronger controlled human evidence regarding the alteration of NAD+-related biomarkers, while direct NAD+ administration has a much more modest base of controlled studies on clinical outcomes. It remains unknown whether either approach yields significant long-term benefits for longevity, cognitive function, energy, or disease prevention.
Limitations of current evidence
The most important limitation is the lack of direct randomized studies comparing oral NMN with direct NAD+ administration under equivalent experimental conditions.
Current comparisons are therefore based primarily on separate studies involving different populations, doses, periods of use, routes of administration, and endpoints.
Data regarding the tolerability of intravenous NAD+ are also limited. The study comparing intravenous NAD+ with intravenous NR was retrospective and conducted in real-world practice settings rather than as a randomized controlled trial. The results help indicate potential tolerability issues, but do not allow for a definitive safety comparison. [5]
Controlled clinical outcome data for direct intravenous or intramuscular NAD+ remain particularly sparse. A 2026 systematic review identified no eligible controlled trials evaluating these methods in anti-aging or wellness applications. [3]
NMN has a stronger human research base regarding increasing blood NAD+ biomarkers, but this should not be equated with proof of broader health benefits. Functional results in studies on NAD+ precursors have been inconsistent, and their long-term clinical significance remains uncertain. [2]
Another limitation is tissue specificity. Changes measured in the blood do not automatically mean equivalent changes in NAD+ in skeletal muscle, brain, liver, heart, or other tissues.
No dedicated human studies evaluating the simultaneous use of direct NAD+ and oral NMN have been identified either. Therefore, claims of additive or synergistic effects remain unconfirmed.
Disclaimer
This article is for educational and scientific-informational purposes only. It does not constitute medical advice, a diagnosis, treatment guidelines, dosage instructions, injection or infusion instructions, or a recommendation for the use of NAD+, NMN, NR, or other NAD+-related compounds.
Research on NAD+ metabolism includes well-understood biochemical mechanisms, as well as the results of cellular, animal, and human studies with varying levels of evidence. An increase in blood NAD+ or related metabolites should not be interpreted as evidence of improved longevity, increased energy, enhanced cognitive function, disease prevention, or the reversal of biological aging.
Direct administration of NAD+, including via intravenous or injection routes, has a limited base of controlled human data for many anti-aging and wellness applications. NMN has stronger data regarding its impact on NAD+-related biomarkers, but its long-term clinical benefits and safety remain not fully established.
Health decisions regarding NAD+-related supplements, intravenous infusions, injections, or other interventions should be discussed with a qualified healthcare professional, especially for pregnant or breastfeeding individuals, those with pre-existing medical conditions, and those taking prescription medications.
References
[1] Yoshino, J., Baur, J. A., & Imai, S. (2018). NAD+ intermediates: The biology and therapeutic potential of NMN and NR. Cell Metabolism, 27(3), 513–528. https://doi.org/10.1016/j.cmet.2017.11.002
[2] Yi, L., Maier, A. B., Tao, R., Lin, Z., Vaidya, A., Pendse, S., Thasma, S., Andhalkar, N., Avhad, G., & Kumbhar, V. (2022). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45, 29–43. https://doi.org/10.1007/s11357-022-00705-1
[3] Gallagher, C., & Emmanuel, O. O. (2026). NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews, 116, 103057. https://doi.org/10.1016/j.arr.2026.103057
[4] Irie, J., Inagaki, E., Fujita, M., Nakaya, H., Mitsuishi, M., Yamaguchi, S., Yamashita, K., Shigaki, S., Ono, T., Yukioka, H., Okano, H., Nabeshima, Y., Imai, S., & Yasuda, K. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal, 67(2), 153–160. https://doi.org/10.1507/endocrj.EJ19-0313
[5] Reyna, K., Heinzen, G., Patel, N., Ritter, M., Siojo, A., Legere, H., & Pojednic, R. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): A retrospective tolerability pilot study in a real-world setting. Frontiers in Aging, 7, 1652582. https://doi.org/10.3389/fragi.2026.1652582